Description
Vitrakvi (larotrectinib) is an oral solution that inhibits tropomyosin receptor kinases, prescribed for certain cancers with NTRK gene fusions. It's a 20 mg/mL concentrate manufactured by Bayer HealthCare Pharmaceuticals Inc. and approved under NDA211710 in December 2022. This information was generated using AI and is provided for informational and research purposes only.
Resources
| Name | Format | Description | Link |
|---|---|---|---|
| Larotrectinib | HTML | Access the FDA dataset for Larotrectinib — ANDA 211710 submitted by Mylan Institutional LLC | Open resource |